<DOC>
	<DOCNO>NCT01592617</DOCNO>
	<brief_summary>The investigator identify three cancer-testis antigen , target cancer vaccination lung cancer . In clinical study , investigator examine use combination three peptide three antigen ( S-488410 ) safety , immunogenicity , antitumor effect vaccine treatment advance non-small cell lung cancer patient .</brief_summary>
	<brief_title>Phase II Study S-488410 Treat Non-small Cell Lung Cancer</brief_title>
	<detailed_description>The purpose study evaluate clinical efficacy safety S-488410 advance non-small cell lung cancer fail standard therapy . The investigator previously identify three novel HLA-A*2402-restricted epitope peptide , derive three cancer-testis antigen , target cancer vaccination lung cancer . In phase II trial , examine use combination three peptide safety , immunogenicity , antitumor effect vaccine treatment HLA-A*2402-positive advance small cell lung cancer patient fail standard therapy .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Advanced NSCLC undergo curative surgery . Patients refractory standard chemotherapy treat therapy due severe adverse effect chemotherapy . Histologically diagnose NSCLC . Clinical efficacy evaluate radiologic method within 4 week prior receive treatment . ECOG performance status 02 within 2 week prior receive treatment . Life expectancy &gt; 3 month . Age 20 79 Male Female . In patient patient . Able willing give valid write informed consent . Other malignancy require treatment radiation , immunotherapy , hyperthermia , surgery . Active uncontrolled infectious disease Active uncontrolled hepatic dysfunction , kidney dysfunction , cardiac disease , lung disease ( i.e . interstitial pneumonia ) . Autoimmune disease . HIVAb antigen positive Prior anticancer therapy within 4 week Laboratory value follow : 2000 &lt; mm3 &lt; WBC &lt; 15000/mm3 , Platelet count &lt; 50000/mm3 , Asparate transaminase &gt; 5 X cutoff value , Alanine transaminase &gt; 5 X cutoff value , Total bilirubin &gt; 3 X cutoff value , Serum creatinine &gt; 3X cutoff value . Patients know HLAA type . Breastfeeding Pregnancy ( woman child bear potential ) Refusal pregnancy conception . Treated S488401 , S488402 , S488403 . Treated investigational drug within 3 month prior receive S48810 treatment . Decision nonenrollment patient principal investigator physicianincharge view point patient 's safety .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>cancer vaccine</keyword>
	<keyword>HLA-A*24:02</keyword>
	<keyword>lung cancer</keyword>
	<keyword>CTL</keyword>
</DOC>